TickerStat.comEloxx Pharmaceuticals annual stock-based compensation
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Stock-Based Compensation Growth & History (ELOX)
Eloxx Pharmaceuticals's stock-based compensation was $235,000 for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $235,000 | −$306,000 | −56.56% |
| 2024 | 2024-12-31 | $541,000 | −$1.4M | −72.47% |
| 2023 | 2023-12-31 | $2.0M | −$1.1M | −34.96% |
| 2022 | 2022-12-31 | $3.0M | −$6.1M | −67.04% |
| 2021 | 2021-12-31 | $9.2M | $501,000 | +5.78% |
| 2020 | 2020-12-31 | $8.7M | −$2.7M | −23.55% |
| 2019 | 2019-12-31 | $11.3M | −$2.0M | −15.21% |
| 2018 | 2018-12-31 | $13.4M | $13.3M | +13137.62% |
| 2017 · Dec 31 | 2017-12-31 | $101,000 | $23,000 | +29.49% |
| 2017 · Jun 30 | 2017-06-30 | $80,108 | −$76,570 | −48.87% |
| 2016 · Dec 31 | 2016-12-31 | $78,000 | −$14,000 | −15.22% |
| 2016 · Jun 30 | 2016-06-30 | $156,678 | −$324,003 | −67.40% |
| 2015 · Dec 31 | 2015-12-31 | $92,000 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $480,681 | −$816,543 | −62.95% |
| 2014 | 2014-06-30 | $1.3M | $572,531 | +79.00% |
| 2013 | 2013-06-30 | $724,693 | −$41,311 | −5.39% |
| 2012 | 2012-06-30 | $766,004 | $15,638 | +2.08% |
| 2011 | 2011-06-30 | $750,366 | $363,727 | +94.07% |
| 2010 | 2010-06-30 | $386,639 | — | — |
Eloxx Pharmaceuticals quarterly stock-based compensation
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $95,000 | $79,000 | +493.75% |
| Q1 2026 | 2026-03-31 | $46,000 | $26,000 | +130.00% |
| Q2 2025 | 2025-06-30 | $16,000 | — | — |
| Q1 2025 | 2025-03-31 | $20,000 | — | — |
| Q4 2023 | 2023-12-31 | $340,000 | −$301,000 | −46.96% |
| Q3 2023 | 2023-09-30 | $418,000 | −$296,000 | −41.46% |
| Q2 2023 | 2023-06-30 | $610,000 | −$134,000 | −18.01% |
| Q1 2023 | 2023-03-31 | $597,000 | −$325,000 | −35.25% |
| Q4 2022 | 2022-12-31 | $641,000 | −$959,000 | −59.94% |
| Q3 2022 | 2022-09-30 | $714,000 | −$1.5M | −67.90% |
| Q2 2022 | 2022-06-30 | $744,000 | −$3.3M | −81.56% |
| Q1 2022 | 2022-03-31 | $922,000 | −$386,000 | −29.51% |
| Q4 2021 | 2021-12-31 | $1.6M | $319,000 | +24.90% |
| Q3 2021 | 2021-09-30 | $2.2M | $810,000 | +57.28% |
| Q2 2021 | 2021-06-30 | $4.0M | $2.1M | +104.20% |
| Q1 2021 | 2021-03-31 | $1.3M | −$2.7M | −67.26% |
| Q4 2020 | 2020-12-31 | $1.3M | −$1.4M | −52.64% |
| Q3 2020 | 2020-09-30 | $1.4M | −$1.5M | −52.18% |
| Q2 2020 | 2020-06-30 | $2.0M | −$1.0M | −34.48% |
| Q1 2020 | 2020-03-31 | $4.0M | $1.3M | +50.30% |
| Q4 2019 | 2019-12-31 | $2.7M | −$1.1M | −28.10% |
| Q3 2019 | 2019-09-30 | $3.0M | $262,000 | +9.72% |
| Q2 2019 | 2019-06-30 | $3.0M | −$3.2M | −51.18% |
| Q1 2019 | 2019-03-31 | $2.7M | $1.9M | +261.63% |
| Q4 2018 | 2018-12-31 | $3.8M | $3.7M | +4639.59% |
| Q3 2018 | 2018-09-30 | $2.7M | $2.7M | +430411.18% |
| Q2 2018 | 2018-06-30 | $6.2M | $6.2M | +61680.00% |
| Q1 2018 · Mar 31 | 2018-03-31 | $735,000 | $724,000 | +6581.82% |
| Q4 2017 | 2017-12-31 | $79,374 | $82,430 | — |
| Q1 2018 · Sep 30 | 2017-09-30 | $626 | −$7,579 | −92.37% |
| Q4 2017 · Jun 30 | 2017-06-30 | $10,000 | −$52,671 | −84.04% |
| Q1 2017 · Mar 31 | 2017-03-31 | $11,000 | $4,825 | +78.14% |
| Q4 2016 | 2016-12-31 | −$3,056 | −$67,413 | — |
| Q1 2017 · Sep 30 | 2016-09-30 | $8,205 | −$15,270 | −65.05% |
| Q4 2016 | 2016-06-30 | $62,671 | — | — |
| Q1 2016 · Mar 31 | 2016-03-31 | $6,175 | −$492,227 | −98.76% |
| Q4 2015 | 2015-12-31 | $64,357 | −$175,681 | −73.19% |
| Q1 2016 · Sep 30 | 2015-09-30 | $23,475 | −$115,658 | −83.13% |
| Q3 2015 | 2015-03-31 | $498,402 | $229,682 | +85.47% |
| Q2 2015 | 2014-12-31 | $240,038 | −$102,753 | −29.98% |
| Q1 2015 | 2014-09-30 | $139,133 | $14,667 | +11.78% |
| Q4 2014 | 2014-06-30 | $561,247 | $388,857 | +225.57% |
| Q3 2014 | 2014-03-31 | $268,720 | $66,546 | +32.92% |
| Q2 2014 | 2013-12-31 | $342,791 | $146,224 | +74.39% |
| Q1 2014 | 2013-09-30 | $124,466 | −$29,096 | −18.95% |
| Q4 2013 | 2013-06-30 | $172,390 | $16,261 | +10.42% |
| Q3 2013 | 2013-03-31 | $202,174 | $327 | +0.16% |
| Q2 2013 | 2012-12-31 | $196,567 | −$87,910 | −30.90% |
| Q1 2013 | 2012-09-30 | $153,562 | $30,011 | +24.29% |
| Q4 2012 | 2012-06-30 | $156,129 | −$26,212 | −14.38% |
| Q3 2012 | 2012-03-31 | $201,847 | $38,556 | +23.61% |
| Q2 2012 | 2011-12-31 | $284,477 | $98,356 | +52.85% |
| Q1 2012 | 2011-09-30 | $123,551 | −$95,062 | −43.48% |
| Q4 2011 | 2011-06-30 | $182,341 | — | — |
| Q3 2011 | 2011-03-31 | $163,291 | — | — |
| Q2 2011 | 2010-12-31 | $186,121 | — | — |
| Q1 2011 | 2010-09-30 | $218,613 | — | — |
Eloxx Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Eloxx Pharmaceuticals's stock-based compensation decreased from $8.7M to $235,000, a change of −$8.4M. The latest reported quarter, Q2 2026, shows $95,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...